Pharmaids Pharmaceuticals Current Share Price | Pharmaids Pharmaceuticals Stock Screener
PHARMAID
Pharmaceuticals
Pharmaids Pharmaceuticals Current Stock Price Today
Live Share Price BSE
₹32.24
▲
0.06 (0.19%)
As of August 21, 2026, the live Pharmaids Pharmaceuticals share price (BSE: PHARMAID) is ₹32.24, up 0.19% from the previous close, with shares trading between ₹32.00 and ₹33.84 in today's trading session, and a 52-week range of ₹26.90–₹62.40.
Analyse PHARMAID price movement history and track historical price performance.
Use the Pharmaids Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Pharmaids Pharmaceuticals Market Cap
₹117.90 Cr.
PHARMAID P/E Ratio (TTM)
-26.75
Pharmaids Pharmaceuticals P/B Ratio
2.47
EPS (TTM)
₹-3.31
Dividend Yield
-
Debt to Equity
0.36
PHARMAID 52 Week High
₹62.40
Pharmaids Pharmaceuticals 52 Week Low
₹26.90
Operating Margin
-18.00%
Profit Margin
25.00%
PHARMAID Revenue (TTM)
₹8.00
EBITDA
₹4.00
Net Income
₹2.00
Total Assets
₹87.00
Total Equity
₹48.00
Pharmaids Pharmaceuticals Current Share Price Chart
Track the current Pharmaids Pharmaceuticals share price and stock price with an interactive chart. Analyse PHARMAID price trends, trading volume, historical performance, and volatility across different timeframes — the complete Pharmaids Pharmaceuticals stock quote in one place.
Pharmaids Pharmaceuticals Company Profile - Fundamental Screener
Screen Pharmaids Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for PHARMAID shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE117D01018
Pharmaids Pharmaceuticals Balance Sheet Screener
Screen PHARMAID balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Assets | |||||
| Total Assets | 87 | 120 | 91 | 25 | 11 |
| Current Assets | 11 | 22 | 14 | 18 | 3 |
| Fixed Assets | 29 | 77 | 63 | 0 | 0 |
| Liabilities | |||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 16 | 36 | 9 | 0 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||
| Total Equity | 48 | 55 | 71 | 23 | 9 |
| Share Capital | 35 | 35 | 35 | 21 | 10 |
| Reserves & Surplus | 12 | 24 | 37 | 1 | -2 |
Pharmaids Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Pharmaids Pharmaceuticals income statement and profit fundamentals.
Analyze PHARMAID quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Pharmaids Pharmaceuticals share price evaluation.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Jun | 2023-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8 | 7 | 6 | 12 | 7 | 5 | 5 | 5 | 5 | 6 | 1 | 0 | 0 | 0 | 0 |
| Expenses | 5 | 8 | 8 | 14 | 12 | 9 | 8 | 8 | 8 | 11 | 3 | 1 | 2 | 2 | 9 |
| EBITDA | 4 | 0 | -3 | -2 | -5 | -4 | -3 | -2 | -4 | -6 | -2 | -1 | -1 | -1 | -9 |
| Operating Profit % | -18.00% | -6.00% | -53.00% | -62.00% | -81.00% | -82.00% | -62.00% | -46.00% | -74.00% | -96.00% | -12200.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 2 | -2 | -4 | -4 | -7 | -5 | -4 | -3 | -4 | -7 | -2 | -1 | -1 | -1 | -9 |
| Tax | 1 | 0 | -1 | -1 | -2 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | 0 | 0 | -2 |
| Net Profit | 2 | -1 | -3 | -3 | -5 | -5 | -3 | -2 | -3 | -6 | -1 | -1 | -1 | -1 | -6 |
| EPS | 0.63 | -0.51 | -0.70 | -0.70 | -1.39 | -1.11 | -0.55 | -0.73 | -0.76 | -2.82 | -0.54 | -0.24 | -0.61 | -0.61 | -4.76 |
Pharmaids Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen PHARMAID cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March |
|---|---|---|---|---|
| Operating Activities | -14 | -11 | -4 | 0 |
| Investing Activities | -12 | -75 | -5 | 1 |
| Financing Activities | 23 | 78 | 21 | 0 |
| Net Cash Flow | -3 | -8 | 12 | 0 |
Pharmaids Pharmaceuticals Shareholding Pattern Screener
See Pharmaids Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings.
Check Pharmaids Pharmaceuticals promoter holding and ownership changes for PHARMAID on TickJournal.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Apr |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 32.99% | 32.99% | 5.22% | 5.14% | 32.99% | 32.99% | 5.64% | 5.64% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 47.44% | 47.59% | 36.59% | 36.35% | 47.02% | 47.24% | 41.06% | 41.06% |
| Other Holding | 19.57% | 19.42% | 58.20% | 58.51% | 19.99% | 19.77% | 53.30% | 53.30% |
| Shareholder Count | 8,406 | 8,632 | 8,220 | 8,026 | 8,027 | 8,288 | 7,554 | 7,567 |
Pharmaids Pharmaceuticals Share Dividend Screener - Share Yield Analysis
Check Pharmaids Pharmaceuticals dividend history with payout and yield data.
View Pharmaids Pharmaceuticals dividend details including ex-dates and amounts for PHARMAID stock.
Pharmaids Pharmaceuticals Stock Index Membership
See which indices include Pharmaids Pharmaceuticals stock.
Check PHARMAID index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Pharmaids Pharmaceuticals Market Events Screener - Corporate Actions
Get Pharmaids Pharmaceuticals corporate actions including splits, bonuses, and buybacks.
Check Pharmaids Pharmaceuticals stock events that may affect PHARMAID share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-12 | 2026-08-12 | Quarterly Result Announcement | NA | 5.59% |
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | -7.35% |
| 2026-02-12 | 2026-02-12 | Quarterly Result Announcement | NA | -0.69% |
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | 0.44% |
| 2025-09-23 | 2025-09-23 | Annual General Meeting | NA | -4.35% |
| 2025-08-21 | 2025-08-21 | Quarterly Result Announcement | NA | 0.00% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | 0.43% |
| 2025-05-23 | 2025-05-23 | Quarterly Result Announcement | NA | -0.31% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | -7.19% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | 21.50% |
| 2024-09-25 | 2024-09-25 | Annual General Meeting | NA | -12.02% |
| 2024-01-31 | 2024-01-31 | Extraordinary General Meeting | NA | -1.74% |
| 2022-12-31 | 2022-12-31 | Extraordinary General Meeting | NA | 47.76% |
Pharmaids Pharmaceuticals Competitors Screener - Peer Comparison
Screen PHARMAID competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 463,072 | 38.12 | 61,674 | 12.69% | 11,565 | 47.09 |
| Divis Laboratories | 225,038 | 77.15 | 11,067 | 13.95% | 2,568 | 71.85 |
| Torrent Pharmaceuticals | 183,832 | 85.40 | 13,886 | 20.34% | 2,138 | 45.42 |
| Cipla | 117,138 | 34.91 | 29,045 | 2.24% | 3,870 | 50.74 |
| Zydus Life Science | 114,228 | 24.76 | 27,658 | 17.64% | 5,026 | 50.68 |
| Lupin | 102,192 | 18.41 | 29,039 | 26.75% | 5,356 | 30.04 |
| Dr Reddys Laboratories | 100,160 | 31.52 | 35,059 | 3.90% | 4,158 | 49.18 |
| Mankind Pharma | 100,160 | 48.34 | 14,636 | 14.85% | 1,938 | 43.34 |
| Laurus Labs | 96,489 | 89.94 | 6,868 | 22.01% | 890 | 61.64 |
| Aurobindo Pharma | 93,332 | 25.95 | 34,145 | 5.56% | 3,503 | 55.68 |
Pharmaids Pharmaceuticals Company Announcements - News Screener
Screen PHARMAID latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-08-21 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-19 | Submission Of Unaudited Financial Results For The Quarter Ended June 30 2026 | - |
| 2026-08-19 | Board Meeting Outcome for Board Meeting Outcome For August 12 2026 | - |
| 2026-08-13 | Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended 30Th June 2026. | - |
| 2026-07-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-30 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-06-26 | Closure of Trading Window | - |
| 2026-06-25 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-06-13 | Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015-Providing Corporate Guarantee To Subsidiary | - |
| 2026-05-31 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-29 | Submission Of Audited Financial Results Along With Auditors Report For The Quarter And Year Ended 31St March 2026 | - |
| 2026-05-29 | Board Meeting Outcome for Board Meeting Outcome For Audited Financial Results For The Quarter And Year Ended March 31 2026 | - |
| 2026-05-22 | Board Meeting Intimation for Consideration And Approval Of Audited Financial Results (Standalone And Consolidated) For The Quarter And Year Ended 31St March 2026. | - |
| 2026-05-08 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-04-24 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-04-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-27 | Intimation Under Regulation 30 Of SEBI LODR | - |
| 2026-03-25 | Closure of Trading Window | - |
| 2026-02-24 | Intimation Of Receipt Of Accreditation By The American Association For Laboratory Accreditation (A2LA) For Testing Of Medical Devices In Biological Field. | - |
| 2026-02-15 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |